scientific founders in Austria and Germany. The driving force is to develop a strong drug portfolio with innovative and effective treatment methods to decrease the side effects and slow down the disease development in order to improve quality of life for people affected by severe immune-related disorders. Cyxone’s portfolio is based on a solid research platform with a type of biological molecules that have proven to work well as a drug for humans. The company’s development portfolio comprises Rabeximod in clinical phase II program for rheumatoid arthritis (RA) and T20K that is in clinical phase I for multiple sclerosis (MS). In future, Cyxone will also use its cyclotide technology to develop new structures that may prove beneficial for patients in other disease areas.